NEW YORK – Singapore diagnostic firms Angsana Molecular & Diagnostics Laboratory and Pathnova Laboratories announced on Wednesday that they have merged to form Archerfish Precision Diagnostics.
Angsana specializes in molecular diagnostics, particularly molecular oncology and clinical next-generation sequencing, while Pathnova specializes in the development and manufacturing of diagnostic products focused on serology and artificial intelligence. Both laboratories are focused on diseases prevalent in Asia and are accredited by the College of American Pathologists, they noted in a statement.
Angsana has previously partnered with Euroimmun to provide allergy diagnosis and testing services in Southeast Asia. They also partnered with Counsyl to commercialize Counsyl's expanded carrier screening test in Hong Kong, and with Agendia to market Agendia's MammaPrint and BluePrint breast cancer tests. It also worked with Admera Health to distribute pharmacogenomics tests in Asia.
Archerfish will serve both the private and public healthcare sectors and intends to advance its use of next-generation sequencing technology beyond cancer to areas like infectious disease detection. It will also develop "data-driven approaches to disease detection through serum proteomics and serological profiling," and plans to integrate AI to refine pattern analysis, it said.
The merger is backed by a consortium of strategic investors including Temasek Life Sciences Laboratory, Temasek Life Sciences Accelerator, the Life Sciences Innovation Fund, and SEEDS Capital. The firm aims to raise at least SDG$50 million ($37.5 million) over the next three years to support its expansion plans. The funding will be used to further develop and commercialize its diagnostic solutions and expand regionally.
Financial terms of the merger were not disclosed.
"Archerfish will address a critical gap in Singapore's clinical laboratory landscape, seamlessly translating scientific evidence into practical, high-quality clinical laboratory solutions," Ian Cheong, director of Archerfish and cofounder of Pathnova, said in a statement.